Boston, MA 03/10/2014 (wallstreetpr) – Stem cell research company Pluristem Therapeutics Inc. (NASDAQ:PSTI) has announced it has been awarded a patent by the Australian patent Office. The new patent is aimed at covering the company’s method and composition of matter, for three dimensional expansions of adipose stromal cells.
The patent also includes methods of treatment using placental cells for diseases such as graft, heart diseases, strokes and burns. Patents for the same had already been issued by patent offices in Russia and South Africa.
Pluristem Commercial scale Cell Manufacturing Process approved by FDA
Good news continue to trickle in for Pluristem Therapeutics Inc. (NASDAQ:PSTI) with recent revelation being the approval of by the FDA of its comparability studies for the Placental eXpanded PLX cell products. The company has also been awarded permission for new commercial scale cell manufacturing process. Pluristem has already implemented a fully automated 3D cell expansion manufacturing platform that uses its culturing technology.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) believes it has the largest scalable and most efficient process for manufacturing cell therapies that is second to none and should be efficient and reliable in terms of production in the coming months. Pluristem now plans to develop and produce a wide range of cell therapy products that should be beneficial for the treatment of multiple disorders.
January 2014 saw Pluristem Therapeutics Inc. (NASDAQ:PSTI) report positive news for its early/mid stage clinical trials that showed how safe its placenta derived stem cells for the treatment of muscle injuries, the trials were also successful for the treatment of orthopedic injuries. The trials showed that patients treated by PLX-PAD showed maximal muscle contraction force than those on Placebo.
The month of January also saw Pluristem Therapeutics Inc. (NASDAQ:PSTI) receive an approval from Paul Ehrlich institute Germany’s Health authority for the supply of cells from its advanced 3D cell expansion manufacturing platform.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) was down on Friday trading session by 3.19% to close the week at low trading margins of $4.09
